Vancomycin Resistant Staphylococcus Aureus refers to the strains of S.aureus that have become resistant antibiotic glycopeptides (vancomycin). Presently three classes of vancomycin-resistant S.aureus (VRSA) have emerged namely high level VRSA, vancomycin-intermediate S.aureus (VISA) and heterogenus VISA.
Global Vancomycin Resistant Staphylococcus Aureus Infection (VRSA) Market: Brief Description
Staphylococcus aureus is an anaerobic gram positive bacteria, commonly found in the respiratory tract of human and on the skin. This strain of bacteria is always not pathogenic but remains a major cause for respiratory diseases, skin infections and food poisoning.
S.aureus strains often promote infections by producing harmful protein toxins. It is anticipated that approximately 20% of the population carries S.aureus in the anterior part of nasal passages and in the skin flora.
S.aureus infection remains one of the most common causes of postsurgical wound infection and nosocomial infections. Penicillin is the most common choice witnessed for the treatment of S.aureus infection but development of resistance from penicillin is commonly seen hence, a combination therapy along with gentamicin is prescribed for the treatment of infections.
In addition, currently some of the strains have developed resistance to B-Lactam antibiotics which are termed as Methicillin resistant S.aureus (MRSA). This type of infection is growing at a rapid rate and is most often found in hospitals, clinics and in community regions.
Likewise, vancomycin resistant Staphylococcus aureus refers to the strains of S.aureus that have become resistant antibiotic glycopeptides (vancomycin). Presently three classes of vancomycin-resistant S.aureus (VRSA) have emerged namely high level VRSA, vancomycin-intermediate S.aureus (VISA) and heterogenus VISA (hVISA).
VISA infection was firstly identified in Japanese hospitals however, later this strain of bacteria is also found in the Asian region. Linezolid, Ceftobiprole, daptomycin, tigercycline and others are the major drugs prescribed for the treatment of VISA infection.
VRSA infection usually reported in people having weakened immune system or to those who are taking vancomycin for a longer duration. The infection is also seen in those people who have undergone surgical procedures.
Global Vancomycin Resistant Staphylococcus Aureus Infection (VRSA) Market: Trends and Prospects
The market for vancomycin resistant Staphylococcus Aureus is increasing due to rising incidences of the infection. Additionally, growth in government and non government awareness program are also other major factors that are expected to drive the growth of this market.
For instance, Centers for Disease Control and Prevention is constantly working with the healthcare facilities, state local health agencies and clinical microbiology agencies. VRSA infections can be treated with various commercially available antibiotics however, most efficient way of controlling the spread of VRSA is maintaining basic hygienic conditions such as proper wound care, washing hands before while contacting directly with the patients and use of disposable gloves.
Global Vancomycin Resistant Staphylococcus Aureus Infection (VRSA) Market: Regional Overview
Geographically, North America and Europe dominates the vancomycin resistant Staphylococcus Aureus market due to rising incidences of VRSA incidences and demand for new innovative drugs. However, during the forecast period these regions are expected to show slow growth due to market maturity, shortened drug lifecycle and generic infiltration.
Asia-pacific region is anticipated to emerge as the fastest growing region in the near future due to growing number of pharmaceutical manufacturers in the Asian countries and also due to the presence of some of the world’s leading generics manufacturers in this region.
Global Vancomycin Resistant Staphylococcus Aureus Infection (VRSA) Market: Key Players
AstraZeneca Plc, GlaxoSmithKline, Forest Laboratories, Cubist Pharmaceuticals and others are some of the major players operating in this market.
Request a brochure of this report to know what opportunities will emerge in the rapidly evolving Vancomycin Resistant Staphylococcus Aureus Infection (VRSA) Market during 2016- 2024
Category: Market Research Publishers and RetailersCompany profile: TMR provides a range of marketing and business research solutions designed for your specific needs. From off-the-shelf syndicated business And market research to made-to-order custom research, we serve our clients to fulfill their immediate as well as ongoing research requirements. We specialize in the following areas: Syndicated Research Each TMR syndicated research report covers a different sector - such as pharmaceuticals, chemical, energy, food & beverage ...
For more information:Make an Inquiry about this report HERE!